Premium
Investigation on the Optimal Hemocompatible Silver Nanoparticles
Author(s) -
Kwon TaeWoo,
Kim Young Ha,
Youn BuHyun,
Park Kang Hyun
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.580.1
Subject(s) - silver nanoparticle , nanotechnology , drug delivery , cytotoxicity , biocompatibility , chemistry , hemolysis , polyethylene glycol , pulmonary surfactant , nanoparticle , polyvinylpyrrolidone , nanomedicine , materials science , in vitro , biochemistry , organic chemistry , immunology , biology
Several recent researches in biological sciences have been focused on nanotechnology and nanomaterials due to their potential convergence in biomedicine. Drug delivery system is one of the examples of biomedical application utilizing nanoparticles. Therefore, silver nanoparticles (AgNPs) can be used in a drug delivery system. However, the effect of cytotoxicity caused by AgNPs is not fully understood. Therefore, determining the optimal characteristics to facilitate the biocompatibility of AgNPs is an important subject for application. In this study, the human erythrocytes were used as an in vitro model to examine the size, dose, and coating surfactant dependent cytotoxicity of AgNPs. Our results demonstrated that polyvinylpyrrolidone (PVP) was a more suitable surfactant than polyethylene glycol (PEG) for capping AgNPs. In addition, we found the existence of particular size and dosage of AgNPs to reduce hemolysis of human erythrocytes. Membrane damage including hemolysis, potassium efflux, protein leakage, and alterations in cell shape and membrane fragility were minimized with 100 nm AgNP particles. This study provides novel insights into AgNPs cytotoxicity and a basis for the utilization of AgNPs for diagnostic and therapeutic applications.